Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on LENZ Therapeutics and keeping the price target at $48.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matthew Caufield has given his Buy rating due to a combination of factors that highlight the potential of LENZ Therapeutics’ LNZ100 eye drop for presbyopia. Key opinion leaders (KOLs) in optometry and ophthalmology have shown positive sentiment towards LNZ100, especially in light of its upcoming PDUFA date in August 2025. These experts emphasize the importance of efficacy, all-day durability without the need for repeat dosing, and a safety profile that minimizes risks such as headaches or retinal complications. The positive feedback from KOLs is particularly significant as it comes from practitioners whose patient base heavily relies on reading glasses, and who have experience with previous eye drop products like VUITY.
Additionally, Caufield notes that LENZ Therapeutics is strategically preparing for commercial success. The company has positioned its sales force for effective marketing upon approval and has secured international licensing and commercialization agreements in key regions such as China, Canada, and parts of Asia. Despite previous disappointments with first-generation products like VUITY, KOLs are optimistic about LNZ100’s novel mechanism of action, which targets the iris sphincter muscle for a rapid and durable effect. This positions LNZ100 as a promising alternative in the multi-billion-dollar presbyopia market, where there is room for multiple effective treatments. These factors collectively support Caufield’s Buy rating for LENZ Therapeutics.
According to TipRanks, Caufield is an analyst with an average return of -6.7% and a 37.29% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Diamedica Therapeutics, Opus Genetics, and LENZ Therapeutics.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $49.00 price target.